MYD88 L265P somatic mutation in Waldenström's macroglobulinemia

New England Journal of Medicine

Volumn 367, Issue 9, 2012, Pages 826-833

  Treon, Steven P ^a   Xu, Lian ^a   Yang, Guang ^a   Zhou, Yangsheng ^a   Liu, Xia ^a   Cao, Yang ^a   Sheehy, Patricia ^a   Manning, Robert J ^a   Patterson, Christopher J ^a   Tripsas, Christina ^a   Arcaini, Luca ^e   Pinkus, Geraldine S ^b   Rodig, Scott J ^b   Sohani, Aliyah R ^c   Harris, Nancy Lee ^c   Laramie, Jason M ^f   Skifter, Donald A ^f   Lincoln, Stephen E ^f   Hunter, Zachary R ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; LEUCINE; MYELOID DIFFERENTIATION FACTOR 88; PROLINE; TRANSCRIPTION FACTOR RELA;

AMINO ACID SUBSTITUTION; ARTICLE; AT RICH INTERACTIVE DOMAIN 1A GENE; B LYMPHOCYTE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IGM MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE; MARGINAL ZONE LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOID DIFFERENTIATION PRIMARY RESPONSE 88 GENE; NUCLEIC ACID BASE SUBSTITUTION; PREMATURE PROTEIN TRUNCATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SANGER SEQUENCING; SEQUENCE ANALYSIS; SOMATIC MUTATION; WALDENSTROEM MACROGLOBULINEMIA; WHOLE GENOME SEQUECING; WILD TYPE;

EID: 84865475885     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1200710     Document Type: Article

References (36)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:110-5.
2. Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008:194-5.
3. Treon SP. How I treat Waldenström macroglobulinemia. Blood 2009;114:2375-85.
4. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17:488-94.
5. McMaster ML, Csako G, Giambarresi TR, et al. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res 2007;13:5063-9.
6. Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a populationbased study in Sweden. Blood 2008;112:3052-6.
7. Kyle RA, Therneau TM, Rajkumar SV, et al. Long term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:3759-64.
8. Morra E, Cesana C, Klersy C, et al. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia 2004;18:1512-7.
9. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005;23:4662-8.
10. Roach JC, Glusman G, Smit AFA, et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010;328:636-9.
11. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010;465:473-7.
12. Drmanac R, Sparks AB, Callow MJ, et al. Human genome sequencing using unchained base reads on self-assembly DNA nanoarrays. Science 2010;327:78-81.
13. The Complete Genomics Analysis Tools (cgatools), v1.3.0 (http://cgatools.sourceforge.net/docs/1.3.0/cgatools-methods.pdf).
14. Carnevali P, Baccash J, Halpern AL, et al. Techniques for human genome resequencing using mated gapped reads. J Comput Biol 2012;19:279-92.
15. Loiarro M, Sette C, Gallo C, et al. Peptide-mediated interference of TIR domain dimerization in MYD88 inhibits IL-1 dependent activation of NF-κB. J Biol Chem 2005;280:15098-14.
16. Powers JP, Li S, Jaen JC, et al. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett 2006;16:2842-5.
17. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 2008;111:5068-77.
18. Kyrtsonis MC, Levidou G, Korkolopoulou P, et al. CD138 expression helps distinguish Waldenström's macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL). Clin Lymphoma Myeloma Leuk 2011;11:99-102.
19. Arcaini L, Varettoni M, Boveri E, et al. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk 2011;11:103-5.
20. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-9.
21. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830-7.
22. Puente XS, Pinol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-5.
23. Euskirchen GM, Auerbach RK, Davidov E, et al. Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet 2011;7(3):e1002008.
24. Mamo A, Cavallone L, Tuzmen S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor suppressor gene in breast cancer. Oncogene 2012;31:2090-100.
25. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012;33:100-3.
26. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43:1219-23.
27. Pottier N, Yang W, Assem M, et al. The SWI/SNF chromatin remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst 2008;100:1792-803.
28. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298-303.
29. Lohr JG, Stjanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole exome sequencing. Proc Natl Acad Sci U S A 2012;109:3879-84.
30. Watters TM, Kenny EF, O'Neill LAJ. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 2007;85:411-9.
31. Loiarro M, Gallo G, Fantò N, et al. Identification of critical residues of the MYD88 death domain involved in the recruitment of downstream kinases. J Biol Chem 2009;284:28093-103.
32. Lin SC, Lo YC, Wu H. Helical assembly in the MYD88-IRAK4-IRAK2 complex in TLR/IL-1R signaling. Nature 2010;465:885-90.
33. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Toll-like receptor dependent responses by IRAK1 and IRAK2. Nat Immunol 2008;9:684-91.
34. Cohen L, Henzel WJ, Baeuerie PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature 1998;395:292-6.
35. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-5.
36. Dimopoulos MA, Chen C, Kastritis E, Gavriatopoulou M, Treon SP. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2010;10:110-7.